Inside informationEnglish
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 23/06/2026, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119040_20260623